TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02564965

Intervention type: DEVICE
Group type: OTHER
Intervention: Double Pigtail Plastic Stent
Description: Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent

Intervention type: DEVICE
Group type: OTHER
Intervention: Double Pigtail Plastic Stent
Description: Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent

Intervention type: DEVICE
Group type: OTHER
Intervention: AXIOS Metal Stent
Description: Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent

Intervention type: DEVICE
Group type: OTHER
Intervention: AXIOS Metal Stent
Description: Patients will be stratified into two arms (Greater than 50% necrosis or less than 50% necrosis), then will be randomized to either the double pigtail plastic stent or AXIOS metal stent
Study: NCT00851877

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab is an epidermal growth factor receptor (EGFR) inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin is an anti-cancer chemotherapy drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-Paclitaxel
Description: paclitaxel albumin-stabilized nanoparticle formulation

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiation therapy
Description: intensity-modulated radiation therapy
Study: NCT03977272

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination drug
Description: Accompanying with modified-FOLFIRINOX, Anti-PD-1 antibody was applied biweekly

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: modified-FOLFIRINOX
Study: NCT04123548

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: StrataGraft skin tissue
Description: StrataGraft skin tissue was delivered as a single topical application to no more than 3 separate burn sites, totaling up to approximately 2000 cm\^2 of treatment area using no more than 20 tissues.
Study: NCT04530656

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Description: Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of middle-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Description: Two doses of middle-dose (20µg/ 0.5ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Description: Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Two doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28
Description: Two doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 28.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
Description: Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Three doses of high-dose recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28
Description: Three doses of high-dose (40µg/ 1.0ml) recombinant SARS-CoV-2 vaccine (Sf9 Cell) at the schedule of day 0, 14, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 28（middle-dose group）
Description: Two doses of placebo (0.5ml) at the schedule of day 0, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 28（middle-dose group）
Description: Two doses of placebo (0.5ml) at the schedule of day 0, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 28（high-dose group）
Description: Two doses of placebo (1.0ml) at the schedule of day 0, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Two doses of placebo at the schedule of day 0, 28（high-dose group）
Description: Two doses of placebo (1.0ml) at the schedule of day 0, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）
Description: Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Three doses of placebo at the schedule of day 0, 14, 28（high-dose group）
Description: Three doses of placebo (1.0ml) at the schedule of day 0, 14, 28
Study: NCT04889586

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EMG-biofeedback armband (REMO)
Description: After clinical evaluation, the subjects execute an instrumental test. By wearing EMG-biofeedback device (REMO), the subjects have to perform 10 different hand gestures: thumb abduction, pinch, finger flexion, finger extension, wrist flexion, wrist extension, forearm pronation, forearm supination, radial wrist deviation and ulnar wrist deviation. The muscle activations (EMG signals) during the execution of each movements, are recorded for 3 seconds.
Study: NCT04350723

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Awake Proning
Description: The duration of proning will be a total of 8-10 hours with 1-2 hours break in supine position.
Study: NCT02553044

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cholecalciferol (Vitamin D3)
Description: Oral vitamin D3 doses made up using 50 000IU ampules of vitamin D3 dissolved in 1ml of olive oil.
Study: NCT03047343

Intervention type: OTHER
Intervention: Retrospective data extraction in medical files
Description: Retrospective data extraction in medical files

Intervention type: OTHER
Intervention: Retrospective data extraction in medical files
Description: Retrospective data extraction in medical files
Study: NCT03625115

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Family Navigator (FN)
Description: The intervention will be a modified Patient Navigator model, that we will refer to as a Family Navigator (FN) model, that will engage, inform, and assist participating parents to follow-through with the process of EI referrals and services. Eligible children randomized to the intervention arm will be provided with services from a FN. The FN will maintain contact with the family, the child's primary care provider, and Early Intervention staff, if applicable, throughout the duration of the study.
Study: NCT04306952

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief MBI
Description: The brief MBI consists of four weekly group sessions that are two hours each and one all day mediation retreat. The rationale for testing the short MBI is to evaluate a low-dose (8 hours of contact) MBI that optimizes cost-effectiveness and minimizes patient burden.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard MBI
Description: The standard MBI consists of eight weekly group sessions that are approximately two hours each and one all day meditation retreat. The length of this package is based on the standard length of MBSR as an 8-week program. The rationale for testing the standard MBI is to provide a comparison to a dose (16 hours of contact) that is most similar to the length of MBSR and has the fewest modifications, making it easier to train MBI providers.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extended MBI
Description: The extended MBI consists of four weekly group sessions followed by four group sessions every other week over the course of 12 weeks. Each group session will be two hours. The group sessions will be identical to the standard package except for the timing (every other week) of the last four sessions. In addition to the group sessions, the MBI provider will offer office hours in between the bi-weekly group sessions, where participants will be able to schedule individual sessions with the MBI provider to discuss questions and troubleshoot their mindfulness practice. In addition, participants will receive an all-day meditation retreat, similar to the other conditions. The rationale for testing the extended MBI is to optimize acceptability and uptake based on the investigator's preliminary data by allowing for a slower, extended pace of learning mindfulness practices with an opportunity to have individual discussions with the instructor (16 hours of contact + individual office hours).
Study: NCT01599936

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anascorp
Description: 3 vials of Alacramyn reconstituted in 50 ml of normal saline as an IV infusion over 10 minutes.
Study: NCT04600817

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ107
Description: QW8

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: TJ107 placebo
Description: QW8
Study: NCT03988881

Intervention type: PROCEDURE
Intervention: Revascularization
Description: PCI or CABG
Study: NCT04296643

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medical Mask
Description: Medical Mask (known also as Surgical Mask)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: N95 respirator
Description: N95 respirator
Study: NCT03121274

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal delivery
Description: vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: vaginal delivery
Description: vaginal delivery is carried by an expert obstetrician and the need for forceps or ventose is recorded
Study: NCT04119375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Keheala Mobile Health Platform and Behavioral Interventions
Description: Keheala is a mobile health company that delivers powerful behavior change interventions from the social sciences across basic feature phones or smartphones to address the nonmedical drivers of disease, which exist away from health facilities.~The intervention includes automated reminders, remote self-verification of doses, accessible TB information and individualized follow-up.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social and Behavior Change Communication (SBCC)
Description: Automated reminders, remote self-verification of doses and accessible TB information. All interactions are behaviorally-informed but do not include regular adherence support/follow-up from study team members as the Keheala intervention does.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS Reminder
Description: Patients receive a single daily SMS message to take their medication.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The standard-of-care protocol in Kenya includes diagnosis, the provision of medications - typically administered for a 1-2 week period at which point patients are expected to return to the clinical site - periodic on-the-ground follow-up by community health volunteers (CHVs)(at the discretion of local clinicians and CHVs) and nutritional support, as is sometimes provided.
Study: NCT00733850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kanglaite Injection plus gemcitabine
Description: Intravenous repeating dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Intravenous repeating dose
Study: NCT02099669

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Red Blood Cell Transfusions

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Red Blood Cell Transfusions
Study: NCT03697174

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 200 ppb ozone group
Description: The exposure group will be exposed to 200 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
Study: NCT02406560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: fasted

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Description: high fat meal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Study: NCT02674880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HMW-HA
Description: Aerolized administration b.i.d.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Standard therapy
Study: NCT00645762

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RS-Series Rhinosinusitis Treatment System
Description: Single arm

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FinESS Balloon
Study: NCT01978730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: high dose group of SaiLuoTong capsule
Description: high dose group of SaiLuoTong capsule: take three pills (180 mg) of SaiLuoTong capsule each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: low dose group of SaiLuoTong
Description: low dose group of SaiLuoTong capsule: take two pills (120 mg) of SaiLuoTong capsule plus one pill of placebo (analog SaiLuoTong capsule) each time, twice a day, 0.5 hours after breakfast and dinner, taking with lukewarm water.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: the control group
Description: The control group is randomly divided into two groups by 1:1. During the first 26 weeks, all subjects will take three pills of placebo each time, twice a day. During the last 26 weeks, the subjects in the placebo group will take two pills of SaiLuoTong plus one pill of placebo or three pills of SaiLuoTong each time, twice a day.
Study: NCT03113877

Intervention type: OTHER
Intervention: Autonomic Dysfunction Testing
Description: The participants with CdLS will complete the COMPASS-31 survey and will complete standard clinical testing for autonomic dysfunction including an autonomic reflex screen (tilt table and quantitative sudomotor axon reflex testing) and thermoregulatory sweat test (TST).
Study: NCT04238754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epidiolex
Description: Epidiolex 100 mg/mL Oral Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epidiolex
Description: Epidiolex 100 mg/mL Oral Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Cherry syrup oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cherry syrup oral solution
Study: NCT01259791

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individual-specific statin causing myopathy
Description: Individual-specific statin causing myopathy vs. placebo
Study: NCT03697174

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: 0 ppb ozone group
Description: The control group will be exposed to 0 ppb ozone in a chamber for 2 hours while alternating 20-min rest and 10-min exercise periods. The exercise workload will be adjusted to achieve the targeted ventilation of 25 \~ 27 L/min(approximately equal to 15 \~ 18L/min/m2 body surface area). The temperature and relative humidity in the chamber will be maintained at 22±1℃ and 55%±5%, respectively.
Study: NCT01732094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triptorelin
Description: Triptorelin 0.1 mg/1 ml solution daily from day 21 of the cycle onwards

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa 150μg
Description: Corifollitropin alfa 150μg (single dose) 2 or 3 weeks after initiation of triptorelin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hpHMG
Description: hpHMG 300IU daily from day 7 following Corifollitropin alfa onwards
Study: NCT02868814

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Release Tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Release Tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00831649

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Study: NCT03106766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acne cream 2X
Description: Twice daily application of facial acne cream 2X after facial cleansing

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acne cream 1X
Description: Twice daily application of facial acne cream 1X after facial cleansing
Study: NCT00628238

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide and Rituximab
Description: Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide and Rituximab
Description: Lenalidomide starting at a low dose and escalated based on patient tolerability 21 days of every cycle. Rituximab at 375mg/m2 administered following the first 21 days of lenalidomide monotherapy, continued weekly throughout cycle 2, and then every 4 weeks for subsequent cycles. Each patient may receive up to a maximum of 7 cycles of treatment if no progressive disease or significant toxicity.
Study: NCT00979797

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based interventions to promote maternal and child health
Description: Promotion of antenatal and postnatal care and safe delivery Essential Newborn care Community case management, and feeding for children.
Study: NCT01245517

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Dietary Phosphorus Education Program
Study: NCT03004573

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuropsychological detailed tests with focus on social cognition
Description: MATTIS, MOCA, BREF, Light points test, PDQ39
Study: NCT02383030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: After randomization patients will receive (Arm A, experimental Arm) fulvestrant as the following schedule: 500 mg i.m. on Days 0, 14, 28 followed by fulvestrant 500 mg im given every 28 days until progression disease. Study will start after 42 days from the last cycle of chemotherapy
Study: NCT02606942

Intervention type: OTHER
Intervention: Questionnaires, physical exam, US of the knee
Description: Function and pain questioners, physical findings and sonographic study of the knee joint

Intervention type: OTHER
Intervention: Questionnaires, physical exam, US of the knee
Description: Function and pain questioners, physical findings and sonographic study of the knee joint

Intervention type: OTHER
Intervention: Questionnaires, physical exam, US of the knee
Description: Function and pain questioners, physical findings and sonographic study of the knee joint
Study: NCT02048982

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Guideline
Description: Physicians will receive information on the Choosing Wisely Guideline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline
Description: Physicians will receive information on the Choosing Wisely Guideline

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guideline
Description: Physicians will receive information on the Choosing Wisely Guideline

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Guideline
Description: Physicians will receive information on the Choosing Wisely Guideline
Study: NCT01259791

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03506763

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral + Placebo Oral
Description: Placebo Oral + Placebo Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac oral + Placebo Oral
Description: Diclofenac oral + Placebo Oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diclofenac oral + scopolamina oral
Description: Diclofenac oral + scopolamina oral
Study: NCT04985019

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Arm I (Prepectoral)
Description: Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Arm II (Subpectoral)
Description: Participants followed the Self-Guided Virtual Reality-based Cognitive Behavioral Therapy for 4 weeks.
Study: NCT03547622

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MAT taper with galantamine
Description: Following taper from MAT (methadone or buprenorphine) participants will be given galantamine daily with access to a CBT4CBT computer program
Study: NCT02904343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: domestic hemodialysis machine
Description: WEGO, DBB-27C

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: imported hemodialysis machine
Description: Fresenius, 4008s
Study: NCT02048982

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cost
Description: Physicians will receive cost information.
Study: NCT03547622

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: MAT taper with placebo
Description: Following taper from MAT (methadone or buprenorphine) participants will be given placebo daily with access to a CBT4CBT computer program
Study: NCT00520130

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab: 375 mg/m(2) intravenous (IV), day 1 for patients with cluster of differentiation 20 (CD20)-positive disease.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Cyclosporine: IV over 2 hours or orally every 12 hours on days -1 to 100, followed by a taper if graft versus host disease (GVHD) does not develop.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Allogenic stem cell transplant (ASCT)
Description: Allogenic stem cell transplant